WINTON GROUP Ltd purchased a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 82,626 shares of the medical research company’s stock, valued at approximately $11,117,000. WINTON GROUP Ltd owned about 0.17% of Charles River Laboratories Intl. as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. lifted its stake in Charles River Laboratories Intl. by 7.0% in the second quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock worth $499,216,000 after purchasing an additional 292,685 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Charles River Laboratories Intl. by 3.8% in the second quarter. Renaissance Technologies LLC now owns 1,515,300 shares of the medical research company’s stock worth $170,108,000 after purchasing an additional 55,000 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Charles River Laboratories Intl. by 5.9% in the third quarter. Wells Fargo & Company MN now owns 1,394,064 shares of the medical research company’s stock worth $187,556,000 after purchasing an additional 77,429 shares during the last quarter. First Trust Advisors LP lifted its stake in Charles River Laboratories Intl. by 56.7% in the third quarter. First Trust Advisors LP now owns 858,962 shares of the medical research company’s stock worth $115,565,000 after purchasing an additional 310,975 shares during the last quarter. Finally, Brown Advisory Inc. lifted its stake in Charles River Laboratories Intl. by 5.4% in the second quarter. Brown Advisory Inc. now owns 702,500 shares of the medical research company’s stock worth $78,863,000 after purchasing an additional 36,219 shares during the last quarter. 96.93% of the stock is owned by institutional investors and hedge funds.

In related news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $120.05, for a total transaction of $149,942.45. Following the transaction, the insider now owns 13,690 shares in the company, valued at $1,643,484.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David P. Johst sold 23,356 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the transaction, the insider now owns 219,849 shares in the company, valued at approximately $29,899,464. The disclosure for this sale can be found here. Insiders have sold 28,671 shares of company stock worth $3,829,160 in the last quarter. 2.10% of the stock is owned by corporate insiders.

CRL stock opened at $136.45 on Friday. Charles River Laboratories Intl. Inc has a 12-month low of $96.70 and a 12-month high of $138.89. The stock has a market capitalization of $6.54 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.71 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.81%. The firm had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $567.58 million. During the same quarter in the previous year, the company earned $1.30 earnings per share. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year. As a group, equities analysts predict that Charles River Laboratories Intl. Inc will post 5.93 EPS for the current year.

CRL has been the subject of several recent research reports. Raymond James raised shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research note on Thursday, August 23rd. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. SunTrust Banks boosted their price target on shares of Charles River Laboratories Intl. to $135.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Robert W. Baird boosted their price target on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Finally, Royal Bank of Canada upgraded shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price objective on the stock in a research report on Tuesday, July 17th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $130.56.

TRADEMARK VIOLATION NOTICE: This report was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://theolympiareport.com/2018/11/10/winton-group-ltd-invests-11-12-million-in-charles-river-laboratories-intl-inc-crl-stock.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.